Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences has a positive growth outlook, primarily driven by its lead product, Ingrezza, which is anticipated to achieve approximately $3 billion in sales by 2028, with potential growth up to $3.5 billion in favorable scenarios. Additionally, the company’s Crenessity product for congenital adrenal hyperplasia (CAH) is projected to surpass $1 billion in peak revenues by 2030. Furthermore, Neurocrine's expansive pipeline, which includes late-stage and early-stage assets across various neurological and endocrine conditions, is expected to contribute significantly to its long-term growth trajectory.

Neurocrine Biosciences faces significant competition risks that could adversely impact its market position and revenue growth. Specifically, the growth of Ingrezza in treating tardive dyskinesia may plateau despite efforts to increase market penetration, while the Huntington’s disease chorea market is already limited and contested by two other approved products. Additionally, the competition from atumelnant in the congenital adrenal hyperplasia market adds further pressure, potentially hindering Neurocrine's ability to expand its offerings and market share.